Comparison of the Efficacy of Pingxiao Capsule and Shendan Sanjie Capsule Combined with CP Program in the Treatment of Non-small Cell Lung Cancer in StageⅣ / 中国药房
China Pharmacy
;
(12): 4200-4202, 2015.
Artigo
em Chinês
| WPRIM
| ID: wpr-501146
ABSTRACT
OBJECTIVE:
To compare the efficacy and safety of Pingxiao capsule and Shendan Sanjie capsule combined with CP program in the treatment of non-small cell lung cancer (NSCLC) in stage Ⅳ.METHODS:
132 NSCLC patients in stage Ⅳwere randomly divided into CP group,CP+Pingxiao group and CP+Shendan Sanjie group. CP group was treated with CP program;based on it,CP+Pingxiao group was orally treated with 6 Pingxiao capsules,3 times a day;CP+Shendan Sanjie group was orally treated with 6 Shendan Sanjie capsules,3 times a day. 21 d was a treatment period,and the efficacy was evaluated after 2 treat-ment periods,improvement of life quality,progression-free survival,1-year survival rate and toxicity reactions were observed. RE-SULTSThe recent effective rate,disease control rate,total improvement rate of life quality,progression-free survival and 1-year survival rate in CP+Pingxiao group and CP+Shendan Sanjie group were significantly higher than CP group,incidences of leukope-nia,thrombocytopenia,gastrointestinal tract and decreased hemoglobin were significantly lower than CP group,the differences were statistically significant(P0.05).CONCLUSIONS:
Both Pingxiao capsule and Shendan Sanjie capsule can be combined with CP program in the treatment of NSCLC in stageⅣ,with good safety.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS